{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:16:36Z","timestamp":1770218196623,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.semnephrol.2003.11.003","type":"journal-article","created":{"date-parts":[[2004,3,11]],"date-time":"2004-03-11T17:54:14Z","timestamp":1079027654000},"page":"147-157","source":"Crossref","is-referenced-by-count":44,"title":["Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points"],"prefix":"10.1016","volume":"24","author":[{"given":"Hans-Henrik","family":"Parving","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per K","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasper","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hovind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Tarnow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2003.11.003_BIB1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.236.16.1861","article-title":"The clinical course of diabetic nephropathy","volume":"236","author":"Kussman","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB2","series-title":"The Kidney","first-page":"1731","article-title":"Diabetic nephropathy","author":"Parving","year":"2000"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/00365517609055274","article-title":"Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment","volume":"36","author":"Mogensen","year":"1976","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF00253407","article-title":"A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy","volume":"20","author":"Parving","year":"1981","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1136\/bmj.294.6588.1651","article-title":"Proteinuria","volume":"294","author":"Borch-Johnsen","year":"1987","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2337\/diabetes.44.11.1303","article-title":"Albuminuria and poor glycemic control predicts mortality in NIDDM","volume":"44","author":"Gall","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/bmj.299.6693.230","article-title":"Prognosis in diabetic nephropathy","volume":"299","author":"Parving","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.285.6343.685","article-title":"Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy","volume":"285","author":"Mogensen","year":"1982","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(83)92462-5","article-title":"Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy","volume":"i","author":"Parving","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB11","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1523-1755.2001.00797.x","article-title":"Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively","volume":"60","author":"Hovind","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/ki.1990.217","article-title":"Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?","volume":"38","author":"Remuzzi","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/(SICI)1096-9136(1998110)15:11<900::AID-DIA709>3.0.CO;2-0","article-title":"Promotion, prediction, and prevention of progression in diabetic nephropathy","volume":"15","author":"Rossing","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diabetes.42.5.715","article-title":"Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients","volume":"42","author":"Rossing","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB19","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","article-title":"The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy","volume":"63","author":"Keane","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB20","first-page":"17A","article-title":"Effect of baseline proteinuria and change in proteinuria with treatment on the risk of renal endpoints in the Irbesartan Diabetic Nephropathy Trial (IDNT)","volume":"13","author":"Atkins","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"issue":"suppl 45","key":"10.1016\/j.semnephrol.2003.11.003_BIB22","first-page":"S174","article-title":"Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease","volume":"45","author":"Apperloo","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB23","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1523-1755.62.s82.13.x","article-title":"Losartan in patients with type 2 diabetes and proteinuria","author":"Shahinfar","year":"2002","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1755.2001.059002702.x","article-title":"Progression of diabetic nephropathy","volume":"59","author":"Hovind","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0140-6736(99)90122-8","article-title":"Renoprotective therapy","volume":"354","author":"de Jong","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0011-393X(99)90003-6","article-title":"The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus","volume":"60","author":"Muirhead","year":"2002","journal-title":"Current Therapeutic Research"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.2000.00224.x","article-title":"Long-term comparison of Losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy","volume":"58","author":"Lacourciere","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ndt\/18.2.293","article-title":"Time course of the antiproteinuric and antihypertensive effect of Losartan in diabetic nephropathy","volume":"18","author":"Andersen","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ndt\/16.4.771","article-title":"Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM","volume":"16","author":"Buter","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB32","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1046\/j.1523-1755.2000.07506.x","article-title":"Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy","volume":"57","author":"Bos","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB33","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/j.1523-1755.2000.00386.x","article-title":"Glomerular permselectivity in early stages of overt diabetic nephropathy","volume":"58","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s001250051259","article-title":"Glomerular hypertension as one cause of albuminuria in type II diabetic patients","volume":"42","author":"Imanishi","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB35","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s001250100546","article-title":"Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension","volume":"44","author":"Bonnet","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB36","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s00125-002-0946-y","article-title":"Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy","volume":"45","author":"Langham","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB37","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1046\/j.1523-1755.1998.00164.x","article-title":"Targeting TGF overexpression in renal disease. Maximizing the antifibrotic action of angiotensin II blockade","volume":"54","author":"Peters","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/diacare.26.1.150","article-title":"Optimal dose of Candesartan for renoprotection in type 2 diabetic patients with nephropathy","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB39","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/ndt\/17.8.1413","article-title":"Optimal dose of losartan for renoprotection in diabetic nephropathy","volume":"17","author":"Andersen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB40","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1681\/ASN.V1341100","article-title":"ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease","volume":"13","author":"Hilgers","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB41","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/01.ASN.0000019409.17099.33","article-title":"Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury","volume":"13","author":"Cao","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/ajkd.2002.29909","article-title":"Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels","volume":"39","author":"Komine","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB43","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB44","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1046\/j.1523-1755.2001.00745.x","article-title":"Add-on angiotensin receptor blockade with maximized ACE inhibition","volume":"59","author":"Agarwal","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.25.1.95","article-title":"Dual blockade of the renin-angiotensin system in diabetic nephropathy","volume":"25","author":"Rossing","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ndt\/17.6.1019","article-title":"Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy","volume":"17","author":"Jacobsen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE-inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB48","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB49","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE-inhibitor in diabetic nephropathy. A randomized double-blind cross-over trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE)","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB51","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal dysfunction complicating the treatment of hypertension","volume":"347","author":"Palmer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF00276965","article-title":"Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy","volume":"27","author":"Parving","year":"1984","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB53","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ki.1997.463","article-title":"Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients","volume":"52","author":"Christensen","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB54","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1046\/j.1523-1755.2001.00946.x","article-title":"Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients","volume":"60","author":"Christensen","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2337\/diacare.26.1.156","article-title":"Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy","volume":"26","author":"Christensen","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/bmj.313.7057.591","article-title":"Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme","volume":"313","author":"Parving","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB57","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1523-1755.1998.00847.x","article-title":"Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy","volume":"53","author":"Jacobsen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB58","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2337\/diabetes.47.9.1507","article-title":"Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: Findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM","volume":"47","author":"Penno","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB59","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1097\/01.ASN.0000092139.19587.51","article-title":"Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy","volume":"19","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB60","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/diacare.26.5.1501","article-title":"Long-term renoprotective effects of Losartan in diabetic nephropathy","volume":"26","author":"Andersen","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1046\/j.1523-1755.2002.00410.x","article-title":"Renoprotective effects of losartan in diabetic nephropathy","volume":"62","author":"Andersen","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB62","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s001250050983","article-title":"Renoprotection in diabetes","volume":"41","author":"Parving","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB63","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2337\/diacare.26.3.569","article-title":"Comparative effects of Irbesartan on ambulatory and office blood pressure","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB64","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.2337\/diacare.26.12.3296","article-title":"Kidney function after withdrawal of long-term antihypertensive treatment in patients with type 2 diabetes and microalbuminuria","volume":"26","author":"Andersen","year":"2003","journal-title":"Diabetes Care"},{"issue":"suppl 82","key":"10.1016\/j.semnephrol.2003.11.003_BIB65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1523-1755.62.s82.14.x","article-title":"Losartan reduces the burden and cost of ESRD","volume":"62","author":"Gerth","year":"2002","journal-title":"Kidney Int"},{"issue":"suppl 2","key":"10.1016\/j.semnephrol.2003.11.003_BIB66","first-page":"A339","article-title":"Proteinuria reduction during antihypertensive therapy predicts renal and cardio-vascular protection in patients with type 2 diabetic nephropathy","volume":"46","author":"de Zeeuw","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB67","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"issue":"suppl A","key":"10.1016\/j.semnephrol.2003.11.003_BIB68","first-page":"7A","article-title":"Angiotensin receptor blockers","volume":"18","author":"Pourdjabbar","year":"2002","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB69","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2003.11.003_BIB70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929503001931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929503001931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T02:37:36Z","timestamp":1623724656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929503001931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0270929503001931"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2003.11.003","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}